The government should use “domestic reference prices” to set new drug prices, then drug companies could use value-based analysis to argue for higher prices, according to a Health Affairs article by two West Health Policy Center executives . That approach would result in a $608 price for remdesivir, which is higher than the low-end value-based price of $390 suggested by the Institute for Clinical and Economic Review, but the West Health authors said market forces would lower prices when...